Investigational Drug Information for Muraglitazar
✉ Email this page to a colleague
What is the drug development status for Muraglitazar?
Muraglitazar is an investigational drug.
There have been 10 clinical trials for Muraglitazar.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2005.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Dyslipidemias. The leading clinical trial sponsors are Bristol-Myers Squibb, Merck Sharp & Dohme Corp., and [disabled in preview].
Summary for Muraglitazar
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,247 |
| WIPO Patent Applications | 1,107 |
| Japanese Patent Applications | 599 |
| Clinical Trial Progress | Phase 3 (2005-08-01) |
| Vendors | 48 |
Recent Clinical Trials for Muraglitazar
| Title | Sponsor | Phase |
|---|---|---|
| An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065) | Bristol-Myers Squibb | Phase 3 |
| An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065) | Merck Sharp & Dohme Corp. | Phase 3 |
| Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes | Merck Sharp & Dohme Corp. | Phase 3 |
Clinical Trial Summary for Muraglitazar
Top disease conditions for Muraglitazar
Top clinical trial sponsors for Muraglitazar
US Patents for Muraglitazar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
